Affiliation:
1. Beijing Tiantan Hospital
2. Capital Medical University Affiliated Beijing Friendship Hospital
3. Peking University International Hospital
Abstract
Abstract
Background There are conflicting data on the potential risks of pancreatic carcinoma associated with glucagon-like peptide 1 receptor agonists (GLP-1RAs).
Aim The study aimed to determine whether GLP-1RAs were associated with increased detection of pancreatic carcinoma based on the FDA Adverse Events Reporting System (FAERS) and clarify its potential mechanisms through keyword co-occurrence analysis.
Method Disproportionality and Bayesian analyses were used for signal detection using reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC), and empirical Bayesian geometric mean (EBGM). Mortality, life-threatening events, and hospitalizations were also investigated. Keyword co-occurrence analysis of publications was adopted to uncover potential molecular mechanisms.
Results A total of 3,073 pancreatic carcinoma cases were related to GLP-1RAs. Five GLP-1RAs were detected with signals for pancreatic carcinoma. Liraglutide had the strongest signal detection (ROR 54.45, 95% CI 51.21-57.90; PRR 52.52, 95%CI 49.49-55.73; IC 5.59; EBGM 48.30). The signals of exenatide (ROR 37.32, 95%CI 35.47-39.28; PRR 36.45, 95%CI 34.67-38.32; IC 5.00; EBGM 32.10) and lixisenatide (ROR 37.07, 95%CI 9.09-151.09; PRR 36.09; 95%CI 9.20-141.64; IC 5.17, EBGM 36.09) were stronger than those of semaglutide (ROR 7.43, 95%CI 5.22-10.57; PRR 7.39; 95%CI 5.20-10.50; IC 2.88, EBGM 7.38) and dulaglutide (ROR 6.47, 95%CI 5.56-7.54; PRR 6.45; 95%CI 5.54-7.51; IC 2.67, EBGM 6.38). The highest mortality rate occurred in exenatide (63.58%). cAMP/protein-kinase, Ca2+ channel, endoplasmic-reticulum stress, and oxidative stress are potential pathogenesis of pancreatic carcinoma resulted from GLP-1RAs.
Conclusion GLP-1RAs, except albiglutide, are associatedwith pancreatic carcinoma based on the pharmacovigilance study.
Publisher
Research Square Platform LLC